経口ワクチン市場：タイプ、用途、エンドユーザー別-2025-2030年の世界予測

経口ワクチン市場の2023年の市場規模は168億3,000万米ドルで、2024年には179億1,000万米ドルに達すると予測され、CAGR 6.48％で成長し、2030年には261億4,000万米ドルに達すると予測されています。

経口ワクチン市場には、感染症予防のために経口投与されるワクチンの市場開拓、生産、流通が含まれ、特に従来の注射ワクチンが物流面で課題を抱えている地域では重要です。経口ワクチンは、注射針や訓練された医療従事者を必要としないため、予防接種率を高めることができます。経口ワクチンは、ロタウイルスやコレラのような下痢を引き起こす病原体と闘うための予防接種プログラムで広く使用されており、この技術はインフルエンザやCOVID-19のような他の感染症についても調査しています。最終用途の範囲には、主に公衆衛生イニシアチブ、ヘルスケア施設、旅行関連の衛生部門が含まれます。市場開拓の原動力となっているのは、感染症の流行の増加、新興国における集団予防接種戦略の必要性、経口ワクチン技術の進歩です。新たなビジネスチャンスは、大規模な研究開発投資、予防接種プログラムの採用増加、経口ワクチン開発のためのメッセンジャーRNA（mRNA）技術の統合の可能性などに起因します。

さらに、市場プレイヤーは低所得地域での流通を強化するため、政府や非政府組織（NGO）との提携に注力すべきです。しかし、規制上のハードル、経口製剤の安定性と有効性の問題、経口ワクチンの有効性に対する社会的懐疑といった課題が成長を阻害する可能性があります。インフラやコールドチェーン・ロジスティクスの限界は、農村部や過疎地ではさらに障壁となります。市場機会を活用するため、公開会社は熱安定性ワクチン製剤の技術革新を優先し、有効性を向上させる新規アジュバントの調査を拡大し、誤った情報に対抗するための一般市民への教育キャンペーンを強化すべきです。より優れた経口デリバリーのためのナノ粒子およびマイクロニードル技術の革新は、市場力学を大幅に強化することができます。市場の性質は保健政策や世界の保健イニシアティブの影響を強く受けるため、共同事業や柔軟な製造能力への投資を視野に入れた戦略的計画を立てることで、市場のダイナミックな需要への適応性を確保し、成長機会を効果的に活用することができます。

市場力学：急速に進化する経口ワクチン市場の主要市場インサイトを公開

経口ワクチン市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 製薬業界による無針ワクチン需要の急増
  • 感染症の増加
  • 費用対効果の高い経口ワクチンの生産と入手可能性の増加
• 市場抑制要因
  • 経口ワクチンの開発・保管コストの高さ
• 市場機会
  • 経口ワクチン製品の開発の高まり
  • 野生動物の疾病管理における経口ワクチンの可能性
• 市場の課題
  • 経口ワクチンの使用に伴う副作用

ポーターの5つの力：経口ワクチン市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：経口ワクチン市場における外部からの影響の把握

外部マクロ環境要因は、経口ワクチン市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析経口ワクチン市場における競合情勢の把握

経口ワクチン市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス経口ワクチン市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、経口ワクチン市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨経口ワクチン市場における成功への道筋を描く

経口ワクチン市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 製薬業界による無針ワクチンの需要急増
    • 感染症の発生率増加
    • 費用対効果の高い経口ワクチンの生産と供給の増加
  • 抑制要因
    • 経口ワクチンの開発と保管にかかるコストが高い
  • 機会
    • 経口ワクチン製品の開発の進展
    • 野生動物における疾病制御のための経口ワクチンの可能性
  • 課題
    • 経口ワクチンの使用に伴う副作用
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 経口ワクチン市場：タイプ別

• 弱毒化
• 非アクティブ

第7章 経口ワクチン市場：用途別

• コレラ
• ポリオ
• 狂犬病
• 呼吸器感染症
• 結核

第8章 経口ワクチン市場：エンドユーザー別

• クリニック
• 病院

第9章 南北アメリカの経口ワクチン市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の経口ワクチン市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの経口ワクチン市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Biogen Inc.
• Bull Bio-NCIPD Ltd.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline PLC
• Janssen Global Services, LLC
• Lumen Bioscience, Inc.
• Novo Nordisk A/S
• Pfizer Inc.
• Sanofi S.A.
• Serum Institute of India Pvt. Ltd.
• Shanghai BravoBio Co., Ltd.
• Takeda Pharmaceutical Company Limited
• Valneva SE
• Vaxart, Inc.
• Zoetis Inc.

LIST OF FIGURES

• FIGURE 1. ORAL VACCINE MARKET RESEARCH PROCESS
• FIGURE 2. ORAL VACCINE MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ORAL VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ORAL VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ORAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ORAL VACCINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ORAL VACCINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ORAL VACCINE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ORAL VACCINE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ORAL VACCINE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ORAL VACCINE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS ORAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS ORAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES ORAL VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES ORAL VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ORAL VACCINE MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. ORAL VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ORAL VACCINE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ORAL VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ORAL VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ORAL VACCINE MARKET DYNAMICS
• TABLE 7. GLOBAL ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ORAL VACCINE MARKET SIZE, BY ATTENUATED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ORAL VACCINE MARKET SIZE, BY INACTIVE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ORAL VACCINE MARKET SIZE, BY CHOLERA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ORAL VACCINE MARKET SIZE, BY POLIO, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ORAL VACCINE MARKET SIZE, BY RABIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ORAL VACCINE MARKET SIZE, BY RESPIRATORY INFECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ORAL VACCINE MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ORAL VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ORAL VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 29. CANADA ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. CANADA ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. CANADA ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES ORAL VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. CHINA ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. CHINA ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. CHINA ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 49. INDIA ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. INDIA ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. INDIA ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. ITALY ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. ITALY ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. ITALY ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. POLAND ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. POLAND ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. POLAND ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. QATAR ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. QATAR ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 118. QATAR ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. ORAL VACCINE MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 147. ORAL VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

The Oral Vaccine Market was valued at USD 16.83 billion in 2023, expected to reach USD 17.91 billion in 2024, and is projected to grow at a CAGR of 6.48%, to USD 26.14 billion by 2030.

The scope of the oral vaccine market encompasses the development, production, and distribution of vaccines administered orally to prevent infectious diseases, particularly in regions where traditional injectable vaccines face logistical challenges. Oral vaccines are crucial due to their ease of administration, which enhances immunization coverage by eliminating the need for needles and trained medical personnel. They are extensively used in immunization programs to combat diarrhea-causing pathogens like rotavirus and cholera, and the technology is being explored for other infections like influenza and COVID-19. The end-use scope primarily includes public health initiatives, healthcare facilities, and travel-related health sectors. Market growth is driven by the increasing prevalence of infectious diseases, need for mass immunization strategies in developing regions, and advancements in oral vaccine technology. Emerging opportunities stem from significant R&D investments, the rising adoption of immunization programs, and the potential integration of messenger RNA (mRNA) technology for developing oral vaccines.

Additionally, market players should focus on partnerships with governments and non-governmental organizations (NGOs) to enhance distribution in low-income regions. However, challenges such as regulatory hurdles, the stability and efficacy issues of oral formulations, and public skepticism toward oral vaccine effectiveness can impede growth. Limitations in infrastructure and cold chain logistics further pose barriers in rural and underdeveloped areas. To capitalize on market opportunities, companies should prioritize innovation in thermal-stable vaccine formulations, expand research into novel adjuvants to improve efficacy, and reinforce public education campaigns to combat misinformation. Innovations in nanoparticle and microneedle technologies for better oral delivery can significantly enhance market dynamics. As the market nature is highly influenced by health policies and global health initiatives, strategic planning aligned toward collaborative ventures and investment in flexible manufacturing capabilities can ensure adaptability to dynamic market demands, harnessing growth opportunities effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Oral Vaccine Market

The Oral Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Surge in the demand for needle-free vaccines by the pharmaceutical industry
  • Growing incidences of infectious diseases
  • Increasing production and availability of cost-effective oral vaccines
• Market Restraints
  • High cost of development and storage of the oral vaccine
• Market Opportunities
  • Rising development in the oral vaccines products
  • Potential of oral vaccines for disease control in wildlife species
• Market Challenges
  • Side effects associated with the use of oral vaccines

Porter's Five Forces: A Strategic Tool for Navigating the Oral Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Oral Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Oral Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Oral Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Oral Vaccine Market

A detailed market share analysis in the Oral Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Oral Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Oral Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Oral Vaccine Market

A strategic analysis of the Oral Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Oral Vaccine Market, highlighting leading vendors and their innovative profiles. These include Biogen Inc., Bull Bio - NCIPD Ltd., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Janssen Global Services, LLC, Lumen Bioscience, Inc., Novo Nordisk A/S, Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Shanghai BravoBio Co., Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Vaxart, Inc., and Zoetis Inc..

Market Segmentation & Coverage

This research report categorizes the Oral Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Attenuated and Inactive.
• Based on Application, market is studied across Cholera, Polio, Rabies, Respiratory Infection, and Tuberculosis.
• Based on End-User, market is studied across Clinics and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Surge in the demand for needle-free vaccines by the pharmaceutical industry
    • 5.1.1.2. Growing incidences of infectious diseases
    • 5.1.1.3. Increasing production and availability of cost-effective oral vaccines
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of development and storage of the oral vaccine
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising development in the oral vaccines products
    • 5.1.3.2. Potential of oral vaccines for disease control in wildlife species
  • 5.1.4. Challenges
    • 5.1.4.1. Side effects associated with the use of oral vaccines
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Oral Vaccine Market, by Type

• 6.1. Introduction
• 6.2. Attenuated
• 6.3. Inactive

7. Oral Vaccine Market, by Application

• 7.1. Introduction
• 7.2. Cholera
• 7.3. Polio
• 7.4. Rabies
• 7.5. Respiratory Infection
• 7.6. Tuberculosis

8. Oral Vaccine Market, by End-User

• 8.1. Introduction
• 8.2. Clinics
• 8.3. Hospitals

9. Americas Oral Vaccine Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Oral Vaccine Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Oral Vaccine Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Biogen Inc.
• 2. Bull Bio - NCIPD Ltd.
• 3. F. Hoffmann-La Roche Ltd.
• 4. GlaxoSmithKline PLC
• 5. Janssen Global Services, LLC
• 6. Lumen Bioscience, Inc.
• 7. Novo Nordisk A/S
• 8. Pfizer Inc.
• 9. Sanofi S.A.
• 10. Serum Institute of India Pvt. Ltd.
• 11. Shanghai BravoBio Co., Ltd.
• 12. Takeda Pharmaceutical Company Limited
• 13. Valneva SE
• 14. Vaxart, Inc.
• 15. Zoetis Inc.